Loading clinical trials...
Loading clinical trials...
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER STUDY OF SAGE-718 USING A KETAMINE CHALLENGE, TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMIC RESPONSE USING MAGNETIC RESONANCE IMAGING IN HEALTHY SUBJECTS
Conditions
Interventions
SAGE-718
Placebo
Locations
2
United States
Sage Investigational Site
Long Beach, California, United States
Sage Investigational Site
Berlin, New Jersey, United States
Start Date
November 12, 2018
Primary Completion Date
March 8, 2019
Completion Date
March 22, 2019
Last Updated
September 17, 2025
NCT00104325
NCT07118891
NCT03878121
NCT01399385
NCT07295717
NCT03807401
Lead Sponsor
Supernus Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions